PER

1.18%

8.4¢ percheron therapeutics limited

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-152

First 152 Last

Share
Profile

Follow
Uboy

4,683 Posts.

1086

10/06/21

15:55

Post #: 53772773
Share

Originally posted by Vinceanna ↑

Alzheimer’s Decision Sends Positive Message to Aussie Biotechs

This is from Dr.G. Price Point of view:

A prominent US physician and consultant to Antisense Therapeutics (ASX:ANP), Dr Gil Price notes the FDA’s approval was based on complex data set. That being the case, Biogen will conduct a controlled trial for the verification of Aduhelm clinical benefit in patients with AD.

“But if Antisense Therapeutics produces similar data, we would expect a similar decision from FDA,” says Price, a former director of the Nasdaq-listed Duchenne muscular dystrophy (DMD) drug developer Sarepta Therapeutics.

Antisense is is planning to pursue FDA “fast track” designation for its DMD drug candidate ATL1102. DMD is an incurable muscle wasting disorder that affects one in every 3600 to 6000 male children.

The company is currently discussing the construct of a proposed phase 2b/3 trial with the FDA.

However Price says the FDA’s decision does not constitute a lowering of standards. “The FDA reviewed data in a very difficult therapeutic area, and made a reasonable decision that offers patients hope,” he says.

“Keep in mind that FDA has been working with Biogen over the past 10 years as a partner, more than an overseer.“

Antisense Therapeutics appreciates the culture at FDA for the development of drugs that treat rare diseases and hopes to build a similar relationship as we continue to move forward.”

Expand

Anna,

Kudos to your research skills - where did you find that nugget?

Most of us here rate Dr Price highly...he is thick with FDA / Janet...from his previous Sarepta days.

Every time Price, Gittleson or Goolsbee are quoted in the press...the value of any 'partnership' deal goes up

The science is great - but the science alone will not get the best ROI for shareholders.

Can't wait for the new indications anns.

Alzheimers, Asthma, GLMD.......

Can't be long now.

Last edited by Uboy: 10/06/21

ANP Price at posting: 22.5¢ Sentiment: Buy Disclosure: Held
21 Upvote

0 Great analysis

Reply

Top Stories

STN

Saturn’s stars have aligned for the gold explorer’s Apollo Project

ITM

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL

KGL sniffs 19% Cu from drilling at Rockface play in NT

LLL

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

RHI

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Climate change to drive market trends to the moon

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

TVN

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

There are more pages in this discussion • 40 more messages in this thread...

First 152 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.4¢		Change -0.001(1.18%)		Mkt cap ! $75.72M

Open	High	Low	Value	Volume
8.4¢	8.4¢	8.3¢	$3.097K	37.23K

Buyers (Bids)

No.	Vol.	Price($)
1	29206	8.3¢

Sellers (Offers)

Price($)	Vol.	No.
8.4¢	118557	1

View Market Depth

No.	Vol.	Price($)
1	29206	0.083
2	30500	0.082
2	58100	0.081
2	160300	0.080
1	100000	0.079

Price($)	Vol.	No.
0.084	118557	1
0.085	98557	2
0.086	6500	1
0.089	135000	2
0.090	386175	4

Last trade - 16.10pm 05/07/2024 (20 minute delay)

PER (ASX) Chart

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-152

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL sniffs 19% Cu from drilling at Rockface play in NT

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Climate change to drive market trends to the moon

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-152

Top Stories

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL sniffs 19% Cu from drilling at Rockface play in NT

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Climate change to drive market trends to the moon

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News